MicroRNA 3140-3p (miR-3140-3p)

MicroRNA 3140-3p (miR-3140-3p) is a small non-coding RNA that acts as a potent tumor suppressor by regulating the expression of multiple oncogenic targets [6, 11]. It functions through post-transcriptional gene silencing, specifically binding to the mRNA of genes such as BRD4, MAP3K3, EGFR, and CDK2 to inhibit their translation or induce their degradation [5, 12]. This multi-targeting capability allows miR-3140-3p to simultaneously disrupt several key signaling pathways, making it particularly effective in overcoming drug resistance, such as resistance to BET inhibitors in neuroblastoma [2, 5]. Currently, miR-3140-3p is being developed as a therapeutic nucleic acid drug, with candidates like MIRX002 and MIRX006 entering clinical development [1, 4]. Clinical trials are investigating its efficacy in aggressive cancers like malignant pleural mesothelioma, where it targets cancer stem cells to prevent tumor growth and recurrence [1]. Its ability to distinguish between normal and cancer cells suggests a favorable safety profile with minimal off-target effects [1]. The molecule is typically delivered using advanced systems like lipid nanoparticles or surfactant peptides to ensure stability and tissue-specific uptake [4]. Overall, miR-3140-3p represents a promising precision oncology tool for treating complex, treatment-resistant malignancies [4, 7].

Other names

hsa-miR-3140-3pMicroRNA 3140MIR3140hsa-mir-3140

MicroRNA mimicry and RNA interference-mediated post-transcriptional silencing of oncogenic mRNAs including BRD4, MAP3K3, EGFR, and CDK2.